Strategic Priority 1:
Strengthening Pediatric Rare Disease Clinical Trial Capacity and Advanced Therapy Medicinal Product Readiness

Goal

To equip Canadian pediatric research institutions and affiliated hospitals to attract, develop, and conduct high-quality, innovative pediatric rare disease clinical trials, especially but not exclusively to Advanced Therapy Medicinal Products (ATMP); and to enhance readiness to administer ATMPs within a research and clinical setting. This is broken down into 5 key initiatives:

  1. Academic Leadership, Guidance and Training

  2. ATMP Standard Operating Procedures (SOPs) Development and Training

  3. Network of Pediatric ATMP Clinical Trials and Delivery-Ready Units

  4. Innovative Models

  5. Centralized Supports for Pediatric Rare Disease Clinical Trials (PRDCTs)

Scroll through below to find out more about these initiatives